dalfopristin

出典: meddic

ダルホプリスチン

quinupristin-dalfopristin

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/09/06 12:06:45」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Treatment of infections due to resistant Staphylococcus aureus.
  • Anstead GM, Cadena J, Javeri H.Author information Medicine Service, South Texas Veterans Health Care System, San Antonio, TX, USA.AbstractThis chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin-dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC within the susceptible range. Linezolid is probably the drug of choice for the treatment of complicated MRSA skin and soft tissue infections (SSTIs); whether it is drug of choice in pneumonia remains debatable. Daptomycin has shown to be non-inferior to either vancomycin or β-lactams in the treatment of staphylococcal SSTIs, bacteremia, and right-sided endocarditis. Tigecycline was also non-inferior to comparator drugs in the treatment of SSTIs, but there is controversy about whether it is less effective than other therapeutic options in the treatment of more serious infections. Telavancin has been shown to be non-inferior to vancomycin in the treatment of SSTIs and pneumonia, but has greater nephrotoxicity. Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA; it is non-inferior to vancomycin in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, rifampin, moxifloxacin, and minocycline are oral anti-staphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are also several drugs with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid, delafloxacin, and JNJ-Q2. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary, and despite our deep bullpen of potential therapies, there are still frequent treatment failures and unfortunate clinical outcomes. The following discussion summarizes the clinical challenges presented by MRSA, the clinical experience with our current anti-MRSA antibiotics, and the gaps in our knowledge on how to use these agents to most effectively combat MRSA infections.
  • Methods in molecular biology (Clifton, N.J.).Methods Mol Biol.2014;1085:259-309. doi: 10.1007/978-1-62703-664-1_16.
  • This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and
  • PMID 24085702
  • Linezolid resistance in Enterococcus faecium isolated in Ontario, Canada.
  • Patel SN, Memari N, Shahinas D, Toye B, Jamieson FB, Farrell DJ.Author information Public Health Ontario, Public Health Laboratory, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. Electronic address: Samir.Patel@oahpp.ca.AbstractRecent studies have described linezolid-resistant MRSA and vancomycin-resistant enterococci (VRE) occurring worldwide, including an outbreak of linezolid-resistant MRSA. The objective of this study was to determine if linezolid-resistant enterococci are present in clinical isolates in Ontario, Canada. From January 2010 to June 2012, all enterococcal isolates submitted to the Public Health Ontario Laboratory (PHOL) for confirmation of VRE and susceptibility testing were included in this study. Of 2829 enterococcal isolates tested, 12 Enterococcus faecium were found to be resistant to linezolid. All linezolid-resistant isolates were also resistant to ampicillin, ciprofloxacin, and vancomycin. In addition, 33% of isolates were non-susceptible to daptomycin, whereas 41% were resistant to quinupristin/dalfopristin. Molecular characterization of these isolates showed that 8/12 isolates (66.7%) contained the mutation G2576T in 23S rRNA, which has been associated with linezolid resistance. Amplification and sequencing of L3- and L4-coding genes did not reveal mutations associated with linezolid resistance. One isolate contained the cfr gene, which is associated with linezolid resistance, and has been found in staphylococcal species and E. faecalis. These data show that occurrence of linezolid resistance is still rare among enterococcal isolates referred to PHOL though detection of cfr in E. faecium is concerning as it has the potential to disseminate among other enterococci.
  • Diagnostic microbiology and infectious disease.Diagn Microbiol Infect Dis.2013 Dec;77(4):350-3. doi: 10.1016/j.diagmicrobio.2013.08.012. Epub 2013 Oct 2.
  • Recent studies have described linezolid-resistant MRSA and vancomycin-resistant enterococci (VRE) occurring worldwide, including an outbreak of linezolid-resistant MRSA. The objective of this study was to determine if linezolid-resistant enterococci are present in clinical isolates in Ontario, Canad
  • PMID 24095643
  • Diversity, distribution and antibiotic resistance of Enterococcus spp. recovered from tomatoes, leaves, water and soil on U.S. Mid-Atlantic farms.
  • Micallef SA, Goldstein RE, George A, Ewing L, Tall BD, Boyer MS, Joseph SW, Sapkota AR.Author information Maryland Institute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD 20742, USA.AbstractAntibiotic-resistant enterococci are important opportunistic pathogens and have been recovered from retail tomatoes. However, it is unclear where and how tomatoes are contaminated along the farm-to-fork continuum. Specifically, the degree of pre-harvest contamination with enterococci is unknown. We evaluated the prevalence, diversity and antimicrobial susceptibilities of enterococci collected from tomato farms in the Mid-Atlantic United States. Tomatoes, leaves, groundwater, pond water, irrigation ditch water, and soil were sampled and tested for enterococci using standard methods. Antimicrobial susceptibility testing was performed using the Sensititre microbroth dilution system. Enterococcus faecalis isolates were characterized using amplified fragment length polymorphism to assess dispersal potential. Enterococci (n = 307) occurred in all habitats and colonization of tomatoes was common. Seven species were identified: Enterococcus casseliflavus, E. faecalis, Enterococcus gallinarum, Enterococcus faecium, Enterococcus avis, Enterococcus hirae and Enterococcus raffinosus. E. casseliflavus predominated in soil and on tomatoes and leaves, and E. faecalis predominated in pond water. On plants, distance from the ground influenced presence of enterococci. E. faecalis from samples within a farm were more closely related than those from samples between farms. Resistance to rifampicin, quinupristin/dalfopristin, ciprofloxacin and levofloxacin was prevalent. Consumption of raw tomatoes as a potential exposure risk for antibiotic-resistant Enterococcus spp. deserves further attention.
  • Food microbiology.Food Microbiol.2013 Dec;36(2):465-74. doi: 10.1016/j.fm.2013.04.016. Epub 2013 May 9.
  • Antibiotic-resistant enterococci are important opportunistic pathogens and have been recovered from retail tomatoes. However, it is unclear where and how tomatoes are contaminated along the farm-to-fork continuum. Specifically, the degree of pre-harvest contamination with enterococci is unknown. We
  • PMID 24010630

和文文献

  • バンコマイシン耐性腸球菌 (特集 外科領域における耐性菌)
  • Isolation and Molecular Characterization of Methicillin-Resistant Staphylococci from Horses, Personnel and Environmental Sites at an Equine Hospital in Turkey
  • 各種抗菌薬に対する2004年臨床分離好気性グラム陽性球菌および嫌気性菌の感受性サーベイランス

関連リンク

関連画像

Quinupristin-dalfopristinDescription Dalfopristin.pngQuinupristin-Dalfopristin in Infectious Dalfopristin http://drugline.org/drug Dalfopristin http://www.medicinabih.info Dalfopristin http://www.medscape.com


★リンクテーブル★
リンク元抗菌薬」「ダルホプリスチン」「ダルフォプリスチン
拡張検索quinupristin-dalfopristin-resistant Enterococcus

抗菌薬」

  [★]

antibacterial drug, antibacterial
抗生剤薬理学抗菌薬一覧抗細菌薬
first aid step 1 2006 p.165

定義

  • 細菌/微生物に静菌作用、殺菌作用を示す物質。結果として、人において病原性を除去する目的で使用される。
  • このうち、微生物によって産生される物質を抗生物質と呼ぶ


作用機序による分類

first aid step 1 2006 p.165
  Mechanism of action Drugs
1 Block cell wall synthesis by inhibition of peptidoglycan cross-linking penicillin, ampicillin, ticarcillin, piperacillin, imipenem, aztreonam, cephalosporins
2 Block peptidoglycan synthesis bacitracin, vancomycin, cycloserine
3 Disrupt bacterial/fungal cell membranes polymyxins
4 Disrupt fungal cell membranes amphotericin B, nystatin, fluconazole/azoles
5 Block nucleotide synthesis sulfonamides, trimethoprim
6 Block DNA topoisomerases quinolones
7 Block mRNA synthesis rifampin
8 Block protein synthesis at 50S ribosomal subunit chloramphenicol, erythromycin/macrolides, lincomycin, clindamycin, streptogramins (quinupristin, dalfopristin), linezolid
9 Block protein synthesis at 30S ribosomal subunit aminoglycosides, tetracyclines, spectinomycin
 ATuSi → あつし


薬物動態

  • 濃度依存性:アミノグリコシド系抗菌薬、ニューロキノロン系抗菌薬
  • 時間依存性:βラクタム系抗菌薬

治療期間

小児

尾内一信 ; 第 39 回日本小児感染症学会教育講演 2 小児感染症の抗菌薬療法 -耐性菌時代の適正使用-
感染臓器・臨床診断 原因菌 投与期間(抗菌薬)
髄膜炎 インフルエンザ菌 7-10日
肺炎球菌 10-14日
髄膜炎菌 7-10日
GBS,腸内細菌,リステリア 21日
中耳炎 <2 歳 10日
2 歳≦ 5-7日
咽頭炎 A 群連鎖球菌 10日(ペニシリン系薬)
5日(セフェム系薬)
肺炎 肺炎球菌,インフルエンザ菌 解熱後3-4日
黄色ブドウ球菌 3-4週間
マイコプラズマ,クラミジア 10-21日
腎臓、膀胱炎、腎盂腎炎 大腸菌,プロテウス,腸球菌 3日
14日
骨髄炎 黄色ブドウ球菌 21日
連鎖球菌,インフルエンザ菌 14日

主要な感染症の抗菌薬投与期間

感染レジマニュ p.27
骨髄炎 4-6週
耳鼻咽喉 中耳炎 5-7日
副鼻腔炎 5-14日
A群溶連菌咽頭炎 10日
肺炎 肺炎球菌 7-10日 or 解熱後3日間
インフルエンザ菌 10-14日
マイコプラズマ 14日(7-10日)
レジオネラ 21日
肺化膿症 28-42日
心臓 感染性心内膜炎 α連鎖球菌 2-4週
黄色ブドウ球菌 4-6週
消化管 腸炎 赤痢菌 3日
チフス 14日(5-7日)
パラチフス
腹膜炎 特発性 5日
二次性 10-14日
胆肝膵 肝膿瘍 細菌性 4-8週
アメーバ性 10日
尿路 膀胱炎 3日
急性腎盂腎炎 14日(7-10日)
急性腎盂腎炎・再発 6週
慢性前立腺炎 1-3ヶ月
髄腔 髄膜炎 インフルエンザ菌 7-10日
髄膜炎菌
肺炎球菌 10-14日
リステリア 21日
敗血症 敗血症 コアグラーゼ陰性ブドウ球菌 5-7日
黄色ブドウ球菌 28日(14日)
グラム陰性桿菌 14日(7-14日)
カンジダ 血液培養陰性化後, 14日

ソース不明

妊婦に避けるべき抗菌薬

  • Antibiotics to avoid in pregnancy
  • Sulfonamides––kernicterus.
  • Aminoglycosides––ototoxicity.
  • Fluoroquinolones––cartilage damage.
  • Erythromycin––acute cholestatic hepatitis in mom
(and clarithromycin––embryotoxic).
  • Metronidazole––mutagenesis.
  • Tetracyclines––discolored teeth, inhibition of bone growth.
  • Ribavirin (antiviral)––teratogenic.
  • Griseofulvin (antifungal)––teratogenic.
  • Chloramphenicol––“gray baby.”
  • SAFE Moms Take Really Good Care.

使っても良い

YN.H-24
  • βラクタム系
  • エリスロマイシン、アジスロマイシン

参考

  • 抗菌薬インターネットブック
まとまっていてよい
[display]http://www.antibiotic-books.jp

抗菌薬一覧

ダルホプリスチン」

  [★]

dalfopristin
シナシッド
ストレプトグラミン系抗菌薬キヌプリスチンquinupristin-dalfopristin



ダルフォプリスチン」

  [★]

dalfopristin
ダルホプリスチン


quinupristin-dalfopristin-resistant Enterococcus」

  [★] キヌプリスチン・ダルホプリスチン耐性腸球菌




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡